Dublin, Nov. 20, 2020 (GLOBE NEWSWIRE) -- The "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering.

The scope of this report includes DTC genetic testing technologies, applications, industry subsegments, major strategic alliances, patents, and companies. The market sizes for next-generation cancer diagnostics are given for 2019, 2020 (estimated) and 2025 (forecasted).

This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and genotyping microarrays.

The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics, and PCR.

The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).

Direct-to-consumer (DTC) genetic testing involves the analysis and interpretation of a person's genome. A consumer can access DTC genetic testing from a commercial company or from a health care provider.

DTC genetic testing has evolved in the past 10 years. Initially, it focused on personal applications outside traditional health care, such as exploring ancestry, and has trended toward interfacing with clinical care in non-traditional ways, such as partnerships between DTC companies with health systems.

Analysis of a customer's genome helps to know about their ancestry inference, disease risks, and other personal traits. Based on this, the main applications include ancestry, health, and lifestyle.

Several factors are driving growth in the DTC genetic testing industry, including a shifting emphasis on health-related applications, the rise of personalized genomics, and increasing convenience of ordering goods and services from virtual at-home settings. This latter trend has been accelerated by the COVID-19 pandemic.

There is rising public awareness of DNA and its impact on health and genetic disorders, ancestry, and lifestyle. These trends are having a favorable impact on the at-home genetic testing market. This report provides an in-depth analysis of the DTC genetic testing industry

Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights Overview

Chapter 3 Overview

Chapter 4 DTC Genetic Technologies

Chapter 5 DTC Genetic Testing Industry

Chapter 6 Industry Acquisitions and Strategic Alliances

Chapter 7 DTC Genetic Testing Markets

Chapter 8 Patents

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/62hajf

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Go here to see the original:
Outlook on the Direct-to-Consumer Genetic Testing Global Market to 2025 - Featuring Genetic Technologies, Illumina & Myriad Genetics Among Others...

Recommendation and review posted by Bethany Smith

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Direct-to-Consumer Genetic Testing: Global Markets and Technologies" - https://www.reportlinker.com/p05987656/?utm_source=GNW

This report reviews the main DTC genetic testing technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR) and genotyping microarrays.

The report then discusses several of the significant large-scale population sequencing initiatives that are contributing to DTC genetic testing development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2019 through September 2020. Industry subsectors analyzed include ancestry, clinical health, recreational health, sequencing data-based blockchain, sequencing instrument, long-read sequencing, sequencing informatics and PCR.

The market for DTC genetic testing is analyzed in depth. The market is analyzed by test purpose (ancestry, health, lifestyle); by technology platform (PCR, genotyping arrays, sequencing); by delivery format (test kits, virtual tests); and by geography (North America, Europe, Asia/Pacific, RoW).

The ancestry market segment is analyzed by technology and by ethnicity (African, Asian, European, Latino, other). The health market segment is analyzed by technology and by disease category (cancer, cardiovascular, complex common, pharmacogenomics, rare diseases and other). The lifestyle market segment is analyzed by technology and by application (genetic relatedness, nutrigenomics, personal traits, weight management/fitness, other)

Market data covers 2019, 2020 (estimated) and 2025 (forecasted).

More than 55 companies in the DTC genetic testing industry are profiled in this report.

The analyst provides a summary of the main industry acquisitions and strategic alliances from January 2019 through September 2020, including key alliance trends.

Report Inludes: - 12 data tables and 39 additional tables - An overview of the global markets and technologies for direct to consumer (DTC) genetic testing - Analyses of global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025 - Information on key genomic regions associated with genetic testing and description of instruments and technologies used for DTC genetic testing - Coverage of DNA sequencing; microarray; and software industries and description of the key initiatives in the genetic testing industry - Detailed analysis of the current market trends, market forecast and discussion of technological, regulatory and competitive elements as well as economic trends affecting the future marketplace for direct to consumer (DTC) genetic testing and impact analysis of COVID-19 on the market - Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry - Profiles of the key companies in the DTC testing industry, including Chendu 23Mofang Biotechnology Co. Ltd (23Mofand), Genetic Technologies Ltd, Illumina Inc., Myriad Genetics Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc.

Summary: Direct-to-consumer (DTC) genetic testing involves the analysis and interpretation of a persons genome. A consumer can access DTC genetic testing from a commercial company or from a health care provider.

DTC genetic testing has evolved in the past 10 years. Initially it focused on personal applications outside traditional health care, such as exploring ancestry and has trended toward interfacing with clinical care in non-traditional ways, such as partnerships between DTC companies with health systems.

Analysis of a customers genome helps to know about their ancestry inference, disease risks and other personal traits. Based on this, the main applications include ancestry, health and lifestyle.

Several factors are driving growth in the DTC genetic testing industry, including a shifting emphasis on health-related applications, the rise of personalized genomics and increasing convenience of ordering goods and services from virtual at-home settings. This latter trend has been accelerated by the COVID- 19 pandemic.

There is rising public awareness of DNA and its impact on health and genetic disorders, ancestry and lifestyle. These trends are having a favorable impact on the at-home genetic testing market. This report provides an in-depth analysis of the DTC genetic testing industryRead the full report: https://www.reportlinker.com/p05987656/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original:
Direct-to-Consumer Genetic Testing: Global Markets and Technologies - GlobeNewswire

Recommendation and review posted by Bethany Smith

Im proud of these labs for being so forward-thinking about ease of use and clinician experience. Feyi Ayodele CEO of CancerIQ

CHICAGO (PRWEB) November 19, 2020

CancerIQ, an enterprise precision health platform for cancer, has formed a network of trusted genetic labs to streamline and inform the genetic test ordering process. The CancerIQ Lab Network increases access to genetic testing and improves the experience for providers and genetic testing labs.

Democratizing access to genetic testing is one of the main tenets of precision health. Genetic testing helps providers identify patients at high risk of developing cancer to establish care plans to preempt a diagnosis.

Unfortunately, the vast majority of patients who meet guidelines for genetic testing go untested. Thats due to several barriers, including workflow issues, lack of awareness, confusion over guidelines, and reimbursement concerns.

CancerIQ added a Lab Network to its offerings to overcome those barriers. The network is a strategic alliance of genetic testing labs that recognize the hurdles and want to improve awareness and adoption of genetic testing.

The five anchor members of the CancerIQ Lab Network are Eurofins EGL Genetic Diagnostics, Eurofins NTD, Invitae, LabCorp and Myriad Genetics.

Im proud of these labs for being so forward-thinking about ease of use and clinician experience, says Feyi Ayodele, CEO of CancerIQ. This network makes genetic testing more scalable and accessible to patients.

Lab Network members are listed within the CancerIQ platform. Clinicians see the list at the point of care, which increases awareness of lab offerings and streamlines the test ordering process. If a test is selected by the healthcare provider, CancerIQ prepopulates the test requisition and insurance prior authorization forms with data collected during the patient encounter.

CancerIQ is also integrated into health systems EHRs, further streamlining the ordering process without extra cost or effort from the labs.

Provider organizations that were early adopters of the CancerIQ Lab Network found that the increased convenience and streamlined workflow enhanced ordering and utilization of tests for appropriate patients.

Additionally, patients had more tests covered by insurance because the CancerIQ platform accurately and thoroughly captures necessary clinical information to avoid a denial.

About CancerIQ CancerIQ's precision health platform enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and most importantly improve patient outcomes.

Share article on social media or email:

More:
CancerIQ Officially Launches Lab Network to Increase Awareness and Accelerate Adoption of Genetic Testing - PR Web

Recommendation and review posted by Bethany Smith

PHOENIX Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine.

In a new study published in JAMA Oncology, scientists with Mayo Clinic's Center for Individualized Medicine conducted genetic testing in more than 3,000 patients who were diagnosed with cancer at Mayo Clinic Cancer Center locations in Arizona, Florida and Minnesota. In all, the scientists found that 1 in 8 patients with cancer had an inherited cancer-related gene mutation. This mutation would not have been detected in half of these patients using a standard guideline-based approach.

"We found that 13.5% of patients had an inherited mutation in a gene associated with the development of their cancer," says Niloy Jewel Samadder, M.D., a Mayo Clinic gastroenterologist and hepatologist, who is the study's author. "Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers."

A genetic mutation can cause a gene to malfunction and lead to a cell becoming cancerous. Although many mutations that cause cancer happen by chance in a single cell, the study confirms that nearly 10%-25% are inherited mutations that set off a cycle of events that can lead to cancer.

Niloy Jewel Samadder, M.D.Dr. Samadder says uncovering these hidden inherited genetic mutations could lead to opportunities for cancer management in families and targeted cancer therapies that can save lives.

In the two-year Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, Mayo Clinic provided free genetic testing and counseling to 3,084 Mayo Clinic patients as part of their standard cancer care. The project, representing the largest known multicenter study of universal testing of patients with cancer, included a broad mix of cancer stages and types, including breast, colorectal, lung, ovarian, pancreatic, bladder, prostate and endometrial cancers.

The researchers were surprised to find that the standard guidelines physicians relied on to determine which patients with cancer should undergo genetic testing were only able to identify 48% of the patients with an inherited genetic mutation.

"More than half of the patients who developed cancer due to inherited mutations were being missed, and that has major implications for family members," Dr. Samadder says.

"Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers." Dr. Samadder

During the study, when the researchers examined the effects of a genetic mutation discovery, they found that one-third of the patients with the highest-risk cancer genes had a change in their medical management, including the type of surgery or chemotherapy they received.

"This targeted treatment would have been lost if the patients had not received genetic testing," Dr. Samadder emphasizes.

"Genetic testing is underutilized in cancer care, both for patients and for their families, often due to outdated guidelines that restrict testing to a narrow group of high-risk patients," says Robert Nussbaum, M.D., chief medical officer of Invitae Corporation. "All cancer patients should have access to complete genetic information that can guide their care and inform their families' health." Dr. Nussbaum was a contributing author on the study.

Sharing genetic risks with family members

Dr. Samadder says equally important to the discovery of a patient's inherited cancer mutation is the potential for patients to share the heretible-cause of their disease with their relatives, allowing family members to pursue care for earlier disease detection and cancer management.

"We can help prevent cancer in their loved ones because it is genetic, and they share these cancer-causing genetic changes with their children, siblings and others in their families," Dr. Samadder explains. "We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family."

All blood-related family members of patients found to have a genetic mutation were offered free genetic testing. Overall, 1 in 5 of these family members underwent testing. The next steps will be to incorporate the study findings into the care of all patients with cancer at Mayo Clinic.

"Steps are being taken to ensure all patients are offered genomic sequencing to better understand the genes that led to the development of their cancer, and how to precisely target treatment and improve survival," Dr. Samadder says.

Genetic sequencing, deletion and duplication analysis, and variant interpretation was performed at Invitae Corporation in San Francisco. Support for this project was provided by the Mayo Transform the Practice Grant, Mayo Clinic's Center for Individualized Medicine, Desert Mountain Members' CARE Foundation, the David and Twila Woods Foundation, and a Faculty Career Development Award from the Gerstner Foundation (NJS).

Dr. Samadder presented his study at the American Society of Human Genetics on Oct. 30, 2020.

Continued here:
Mayo Clinic study finds 1 in 8 patients with cancer harbor inherited genetic mutations - Greater Milwaukee Today

Recommendation and review posted by Bethany Smith

(Award-winning tech columnist Jon Markman publishes of Strategic Advantage, a popular daily newsletter about the digital transformation of business, entertainment and society -- and how to invest in it. Click here for a free two-week trial.)

COVID-19 is surging throughout the country, creating an opportunity for agile diagnostic businesses. This is how one newcomer is building an empire.

Elon Musk made news last week when the Tesla ((TSLA) -Get Report) founder claimed to test both positive and negative for the novel coronavirus, twice. Forty five weeks into the global pandemic and the United States still has a testing problem.

Fulgent Genetics ((FLGT) -Get Report), a smaller company with a $908 million market cap that most investors dont know, has a solution.

The problem, apart from the raging infection rates globally, is that not all tests are created equally.

Some, like the four given to Musk, are based on antigens. These so-called rapid tests look for viral proteins called antigens that are found in the surface of the virus. They also have the added benefitting of being inexpensive, at about $5 per test.

The gold standard is polymerase chain reaction variant. PCR tests detect viral genetic material through a process called amplification. They are far more accurate but can cost between $50 to $100 each. They also must be sent away to labs for diagnostics, creating delays of up to a week.

Given the costs and the absence of national testing protocols, businesses, state and local governments have veered toward rapid tests. The Food and Drug Administration, in July granted emergency approval for the use of six rapid tests. And in September the Trump administration began deploying 150 million of these tests across the country.

There is a big problem, though. Antigen tests can only detect proteins 5-7 days after the onset of symptoms. Researchers have determined that infectiousness may last up to 10 days. The result has been a lot of bad data and even greater spread of the virus.

In the week ended Nov. 7, the Center for Disease Control found COVID-19 positivity increased 8.4% week-over-week. A week later, the Washington Post reported that the number of new cases reached 167,276.

The solution seems to be a high quality but low cost PCR test with fast turnaround times.

Fulgent Genetics makes such a test. The company also the platform to deliver tests at scale.

The Temple City, Calif.-based company began in 2011 as a genetic testing platform. The founders worked with clinicians and patients to deliver reliable genetic tests for couples looking to become pregnant or for individuals susceptible to cancer or cardiovascular disease. A Fulgent test was a reliable way to learn about potential genetic risks at a reasonable cost.

The business changed course on March when the novel coronavirus started to impact Americans. Managers quickly leveraged the company diagnostic platform for COVID-19 testing. They hired new staff and built mobile labs in the company parking lot. They saw what the platform could become.

This was possible because the core technology was built from the ground up by engineers, not geneticists. They used parallel processing and machine learning artificial intelligence to process tests quickly and cost effectively. They built in extreme scalability.

Ming Hsieh, chief executive officer, last week spoke to that scale. During the third quarter financial results conference call Hsieh said that with only a modest investment in infrastructure, Fulgent was able to grow test volume by 5,000% year-over-year. During the same time frame gross margins improved by 19% sequentially. Quarterly profits doubled to $63.5 million.

In September the company contracted with New York public school system, the largest in the country. Fulgent will provide a self-administered, at home PCR test with results available within 24 hours. The deal follows another blockbuster deal in July for Los Angeles County for drive through PCR testing.

Its rare for a company of Fulgents size to be in the running for such contracts, let alone win them.

Musk said on Saturday said he would seek a PCR test after 4 antigen tests proved inconclusive.

Investors should expect this scenario to play out time and again as COVID-19 cases continue to expand. Fulgent is in the right place at the right time with the right product.

Shares trade at only 8.5x forward earnings and the market capitalization is still less than $1 billion. Given the sales leverage the stock could trade to $75 within 12 months, or 76% above current levels.

Investors should consider buying Fulgent into any material weakness.

See the article here:
Small Covid Test Maker Is Going Viral - TheStreet

Recommendation and review posted by Bethany Smith

As a nationwide telehealth medical practice, Genome Medical has assembled an extensive team of clinical genetic experts, including board-certified genetic counselors, medical geneticists and other specialists. This team delivers education, risk assessment, access to genetic testing and specialty care referrals -- all through virtual visits. During the COVID-19 pandemic, when two out of five Americans have avoided or delayed medical care1, access to safe virtual services is essential to ensure people at greatest risk are receiving the care they need. Genetic services support the diagnosis and care management of hereditary conditions and the identification of patients at an elevated risk for disease.

Some of the largest payers in the United States are recognizing the critical role geneticists and genetic counselors play. Their members can now self-refer and get in-network access to Genome Medical's genetic experts, and the payer's contracted providers can also make in-network referrals for their patients.

The 90 million covered lives are across multiple payers, including (in part):

"Genome Medical brings together telemedicine and genomics to tackle the rising need for genetic experts to guide patients and providers in making appropriate decisions around 1) who should get genetic testing, 2) which test is optimal and 3) how clinical care should be changed based on test results," said Steven B. Bleyl, M.D., Ph.D., chief medical officer of Genome Medical. "Patients can be seen sooner, and through telehealth, we extend the reach of genetic services to rural communities and underserved areas that have less access to in-person care. Genome Medical is a flexible and cost-effective solution for payers and their members."

Genome Medical can see 85% of cancer patients more quickly than in a traditional clinic setting.2 And in areas like pediatric genetics, where wait times of six months or more for an appointment are common, Genome Medical's growing clinical team can often see patients within a few days. The company's genetic experts are licensed in all 50 states and provide clinical genetics expertise across six major specialty areas: cancer, reproductive health, proactive health, pediatrics/rare disease, pharmacogenomics and cardiovascular genetics. Genome Medical's innovative services are trusted and utilized by health systems, hospitals, testing labs, payors, providers and employers.

Genome Medical is also committed to leveraging advanced technology-enabled solutions to transform the delivery of standard-of-care genetic health services. Beyond wider and accelerated access, the company's technology delivers a 5.5X return on investment in genetic services, while also reducing the cost of care by up to 75 percent.3,4 Its Genome Care DeliveryTM platform creates an efficient and comprehensive experience, including patient engagement and care navigation, risk assessment, self-directed education and informed consent through the Genome Care NavigatorTM, multi-modality patient support, and peer-to-peer provider consultations.

"We are pleased to see health plan partners continue to expand in-network coverage for our genetic health services," said Lisa Alderson, co-founder and CEO of Genome Medical. "It is estimated that tens of millions of patients in the United States meet medical management guidelines for referral to genetics, but most are still being missed. These patients could benefit from the advancements made in utilizing genomics for prevention, diagnosis and treatment. Giving their members access to Genome Medical and telegenetics is a significant step payers are taking in removing historical barriers."

About Genome MedicalGenome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care. Through our nationwide network of genetic specialists and efficient Genome Care DeliveryTM technology platform, we provide expert virtual genetic care for individuals and their families to improve health and well-being. We also help health care providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care. We are shepherding in a new era of genomic medicine by creating easy, efficient access to top genetic experts. Genome Medical is headquartered in South San Francisco. To learn more, visit genomemedical.com and follow @GenomeMed.

References

SOURCE Genome Medical

Homepage

Link:
Genome Medical Reaches 90 Million Covered Lives in US - PRNewswire

Recommendation and review posted by Bethany Smith

In multiple solid malignancies, including breast, ovarian, colorectal, and pancreatic cancers, there is a subset of patients with a hereditary predisposition for these diseases, but the current testing criteria do not mention this subset. In an effort to provide more information of genetic testing in this population, a study of Memorial Sloan Kettering Cancer Center (MSKCC) patients was conducted to test the traditional guideline-based method of testing versus universal testing of a broad cancer patient population over a 5-year period.

A total of 7235 patients were included in the analysis and tested for 76 to 88 cancers. Through this study, investigators uncovered pathogenic and likely pathogenic (P/LP) variants in 7.5% (95% CI 6.6%- 8.4%) of 3,341 patients with breast cancer, 17.4% (95% CI, 14%- 21.6%) of 384 those with ovarian cancer, 13.5% (95% CI, 9.8%- 18%) of 252 patients with colorectal, and 8.8% (95% CI, 5.1%-14.8%) of 136 patients with pancreatic cancer.

Overall, the study found that testing with universal method was comparable to the guideline-based method, implying that universal testing can expand genetic testing to patient populations who are in need but are currently underserved.

In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology (AMP) Annual Meeting, Ozge Ceyhan-Birsoy, PhD, assistant directorof the Laboratoryfor Molecular Medicine, MSKCC, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.

TARGTED ONCOLOGY: In recent years, what advances have we see in cancer genetics?

Ceyhan-Birsoy: There have been significant advances in the range of genetic testing options for cancer patients in recent years. More patients are now able to receive molecular testing on their tumors to identify optimal targeted therapies for their cancer and germline genetic testing to uncover hereditary cancer predisposition. A paired analysis of tumor and normal DNA is increasingly being adapted, which improves the interpretation of both somatic and germline mutations. Additionally, incorporation of RNA analysis has expanded the scope of mutations that can be detected and characterized. Finally, the use of cell-free DNA now allows us to profile a patients tumor using only their blood.

TARGETED ONCOLOGY: How can hereditary predisposition inform oncologist for care/treatment decisions?

Ceyhan-Birsoy: Identifying hereditary mutations that predispose patients to cancer has important implications for their treatment and management. There are established targeted therapies available now for certain germline defects. For instance, germline mutations in certain homologous recombination and mismatch repair genes can predict response to PARP inhibitor and immune-checkpoint inhibitor therapies, respectively. Some therapies may pose high risk for patients with particular gene mutations, such as radiation therapy risks for patients with germline TP53 mutations. In addition, identifying hereditary cancer predisposition is critical to allow timely surveillance and prophylactic interventions for future cancers that the patient may be at higher risk of developing. As germline mutations are heritable, this information provides the opportunity for early surveillance in the patients family members, as well.

TARGETED ONCOLOGY: Can you explain how this MSKCC study came about?

Ceyhan-Birsoy: Genetic testing for hereditary cancer predisposition is traditionally performed in a guideline-dependent and targeted manner. In current practice, only patients who meet established criteria from national and professional organizations receive genetic testing and typically get tested for a small number of genes selected based on their tumor type, age of onset, and family histories. MSKCC has been 1 of the first institutes to pilot a universal testing approach for cancer patients, providing comprehensive germline testing of all known cancer predisposition genes without pre-selection of patients based on traditional genetic testing criteria. We have been performing both targeted and universal testing for our patients since 2015.

In this study, we aimed to understand how the yields (positive rates) of these 2 testing approaches compare to each other in greater than 4000 patients who had traditional and more than 9,000 patients who had universal testing at MSKCC in the past 5 years. We also assessed whether universal testing identified additional findings that would have been missed in a targeted testing approach for any given patient.

TARGETED ONCOLOGY: What are the key results of this analysis?

Ceyhan-Birsoy: We saw that universal germline testing without preselection of patients based on current guidelines yielded comparable rates of positive results to traditional guideline-dependent testing approach, particularly in patients with breast, ovarian, and pancreatic cancers. In addition, universal testing uncovered mutations that predispose to other cancers in about 9% of patients in genes that are not routinely tested for their diagnosis. Approximately half of those conferred high to moderate risk to cancer and about 40% of them implicated early surveillance or prophylactic surgery recommendations to prevent other cancers.

TARGETED ONCOLOGY: What is a key takeaway from your AMP 2020 presentation and explain the implications of these findings?

Ceyhan-Birsoy: Our results suggest that the preselection of patients for genetic testing based on the current guidelines may not significantly increase the likelihood of identifying a germline mutation in certain patient populations. A universal and comprehensive testing approach further provides the benefit of identifying hereditary risk for other cancers, allowing early surveillance and prophylactic interventions.

TARGETED ONCOLOGY: How can this information be applied in oncology clinics?

Ceyhan-Birsoy: Our study underlies the advantages of universal and comprehensive testing for cancer patients. However, there are many challenges that may limit the application of this approach for all cancer patients, including the cost of testing, resources needed to provide pre-test and post-test genetic counseling to patients, and the potential to discover more variants of uncertain significance that may lead to higher number of inconclusive results. Future efforts should be dedicated to providing wider groups of cancer patients access to genetic testing, which can aid in their clinical care and in the care of their family members.

Read more from the original source:
Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors - Targeted Oncology

Recommendation and review posted by Bethany Smith

Global DTC Genetic Testing Market Analysis Report is a deep study of latest DTC Genetic Testing market statistics, trends, and growth scenario. This report offers DTC Genetic Testing market details based on market analysis from 2015-2019 and the forecast of DTC Genetic Testing market information up to 2026. Global DTC Genetic Testing report basically presents industry overview, market development scenario, market segment, and price structures.Various factors directly or indirectly contributing to the DTC Genetic Testing markets like sociology, economics, technological improvement, and changes are covered in this report. This report covers DTC Genetic Testing market size, major companies, their company profile and sales information.The tremendous market competition, DTC Genetic Testing regional analysis, and market demand are covered in this report. This report is a systematic study which declaring the product definition, cost, applications, and market revenue.

List Of Key Players

Helix23andMePathway GenomicsLaboratory Corporation of AmericaThermo FisherWeGeneMapMyGenomeGene by GeneAfrican AncestryColor GenomicsMyriad GeneticsQuest Diagnostics

DTC Genetic Testing Market Segmentation: By Types

Disease Risk and HealthAncestry or GenealogyKinshipLifestyle

DTC Genetic Testing Market Segmentation: By Applications

On-line SalesDoctors Office

Download Free Sample Pdf Report @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-dtc-genetic-testing-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59711#request_sample

The research report on Global DTC Genetic Testing Market evaluates market demand, supply / demand condition, market size of DTC Genetic Testing, import / export scenario and the recent news from the sector. The major areas covered by this study DTC Genetic Testing include North America, Europe, the Middle East, South America and the Asia-Pacific areas. This study evaluates the competitive landscape perspective of main players DTC Genetic Testing, their business profiles, growth elements, and income. This study mentions past, current and forecast market trendsDTC Genetic Testing that will lead to growth. This study also analyzes significant players DTC Genetic Testing on the basis of SWOT analysis to assist readers in creating company plans.

Global DTC Genetic Testing Report conducts a deep study of the potential buyers, market scope, DTC Genetic Testing production volume, consumption ratio, market presence and cost analysis. This report analysis major DTC Genetic Testing market driving forces, growth opportunities and limitations to the market growth. All the qualitative and quantitative aspects of the DTC Genetic Testing market, market value, current trends along with challenges and opportunities will forecast growth in coming years.

InquiryHere For More Details https://www.reportspedia.com/report/life-sciences/2015-2027-global-dtc-genetic-testing-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59711#inquiry_before_buying

In short, the Global DTC Genetic Testing report will answer all the questions related to related to sales, growth strategies followed by major manufacturers, technological advancements, and futuristic DTC Genetic Testing market demands.

Table Of Content:

First chapter covers overview of Global DTC Genetic Testing Market

Regional Market(Production, Demand, Trade) Analysis

Global Market Key Manufacturers Analysis

Global DTC Genetic Testing Market Consumption and Growth Rate Analysis and Forecast (2018-2023)

Global DTC Genetic Testing Market Status and SWOT Analysis by Regions

Global DTC Genetic Testing Market Analysis and Forecast by Type and Application

Global DTC Genetic Testing Market Analysis and Forecast by regions

Global DTC Genetic Testing Industry Barriers, Suggestions and SWOT and Feasibility Analysis

Appendix, Research Finding, Assumptions, and Conclusion

Browse Detailed Table Of [emailprotected] https://www.reportspedia.com/report/life-sciences/2015-2027-global-dtc-genetic-testing-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/59711#table_of_contents

Go here to read the rest:
Global DTC Genetic Testing Market 2020 Comprehensive analysis with Top Manufacturers, Trends, Share, Future Growth Opportunities & Forecast by...

Recommendation and review posted by Bethany Smith

The report on Preimplantation Genetic Testing, documents a comprehensive study of different aspects of the Preimplantation Genetic Testing Market. It focusses on the steady growth in market in spite of the changing market movement. Every market intelligence report covers certain important parameters that can help analysts define the market situation. It includes a thorough analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It also covers methodical researches. This report on Preimplantation Genetic Testing is also based on a meticulously structured methodology. These methods help forecast markets on the basis of detailed research and analysis. Generally, research includes information about manufacturers, vendors, products, consumers, research papers and more. The analysis part mostly includes qualitative and quantitative analysis of markets focusing on business models, market forecasts, market segmentations and other aspects that help in analysis. Every market research study gives specified importance to manufacturers dwelling in that market. A detailed analysis of manufacturers or key players is essential for all new comers entering the market. Competitive analysis or competitor study includes detailed information of manufacturers business models, strategies, revenue growth and all the data required that would benefit the person conducting the market research. For new investors and business initiatives market research is a must as it gives them a direction and a plan of action to move forward keeping in mind their competitors.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1483

Market segmentation is one of the most important aspects of any market research report. Market segmentation is mostly based on demography, geography and behavior. It helps understand the consumers and their demands and behavior towards a particular product or service. Another important aspect covered in any market research report and is also a part of market segmentation is the regional segmentation. This section focusses on the regions with significant advancements in a particular market. Regional analysis of any market gives a detailed overview of regions which have more business opportunities, revenue generation potential and opportunities for future growth. For any new business establishment or business looking to upgrade and make impactful changes in their businesses, this particular section in a report is very important. In this Preimplantation Genetic Testing report, North America is seen as the most dominant region. For many markets this region is of extreme importance. This report gives detailed information of market size and price of this region and other important regions like South America, Asia, Europe and Middle East. This report on Preimplantation Genetic Testing covers all the aspects of a market study and provides a concise conclusion to its readers.

Top leading companies are

Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Read complete report at: https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

The research study is also known to provide in depth analysis of the reports which is one of the key aspects for the growth of the global keyword market. The report is also used in the analysis of the growth rates and the threats of new entrants, which are used for the determination of the growth of the market for the estimated forecast period. Moreover, increased demand for the factors influencing the growth of the market is also one of the major aspects which are likely covered in depth in the report. Market research study determines the increase in changes and the aspects which are likely to have an impact on the growth of the Global Preimplantation Genetic Testing Market. Moreover, increased demand for the technologies is also one of the factors, which are likely to boost the growth of the market research industry.

Preimplantation Genetic Testing Market Segmentation

Market by Type

by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

This report is filled with significant statistics and information for the consumers to attain in-depth data of the Preimplantation Genetic Testing and further Preimplantation Genetic Testing growth. It also focuses and highlights the strategies and the trends, in which the manufacturer and the company are likely to move. One of the methods for the determination of the growth of the market is the increased use of the statistical tools, which is used for the estimation of the growth of the market for the estimated forecast period.The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Preimplantation Genetic Testing report studies the current state of the market to analyze the future opportunities and risks. Preimplantation Genetic Testing report provides a 360-degree global market state. Primarily, the report delivers Preimplantation Genetic Testing introduction, overview, market objectives, market definition, scope, and market size valuation.

In addition, the political and the environmental factors are also determined affecting the global keyword market in the estimated forecast period. The study also provides detailed analysis of the market, which consists of the growth of the regions, which is one of the major aspects which are likely to have an impact on the market. The study covers the production, sales, and revenue of various top players in the global Preimplantation Genetic Testing market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them head on and grasp the maximum market share. The strengths and the political factors, which are likely to affect the market is also covered in detail for the estimation of the market in the estimated forecast.

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1483

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

More:
Global Preimplantation Genetic Testing Market Is Booming Globally | Most recent Report with Analysis | Future Possibility | Coronavirus Effect and...

Recommendation and review posted by Bethany Smith

The study on global Preimplantation Genetic Testing Market, offers profound understandings about the Preimplantation Genetic Testing Market covering all the essential aspects of the market. The report provides competitive pipeline landscape of the global Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of market valued in the year 2019 and its growth in the coming years till 2025. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. A significant development has been recorded by the market of Preimplantation Genetic Testing, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. The report also focuses majorly on the factors like market revenue share, price and production. The company profile section offers the detailed analysis about the expansion policies of companies.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1483

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players. This Preimplantation Genetic Testing report also provides the readers with detailed figures at which the Preimplantation Genetic Testing Market was valued in the historical year and its expected growth in upcoming years. This report on Preimplantation Genetic Testing has been made in order to provide deep and simplified understanding of the market to its end users. In addition, the report include deep dive analysis of the market, which is one of the most important features of the market. Furthermore, the need for making an impact is likely to boost the demand for the experts which are working in the market. Moreover, an in depth analysis of the competitors is also done to have an estimate for the market.

Top key players includes:

Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Read complete report at: https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

The study of various segments of the global market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

Market Segmentation

Market by Type

by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

The research study is also known to provide in depth analysis of the reports which is one of the key aspects for the growth of the global keyword market. The report is also used in the analysis of the growth rates and the threats of new entrants, which are used for the determination of the growth of the market for the estimated forecast period. One of the methods for the determination of the growth of the market is the increased use of the statistical tools, which is used for the estimation of the growth of the market for the estimated forecast period.

The study covers the production, sales, and revenue of various top players in the global Preimplantation Genetic Testing market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them head on and grasp the maximum market share. This report is filled with significant statistics and information for the consumers to attain in-depth data of the Preimplantation Genetic Testing and further Preimplantation Genetic Testing growth. The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Preimplantation Genetic Testing report studies the current state of the market to analyze the future opportunities and risks. Preimplantation Genetic Testing report provides a 360-degree global market state. Primarily, the report delivers Preimplantation Genetic Testing introduction, overview, market objectives, market definition, scope, and market size valuation.

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1483

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Read more:
Preimplantation Genetic Testing Market Outlook and Opportunities in Grooming Regions with Forecast to 2027 - The Daily Philadelphian

Recommendation and review posted by Bethany Smith

Genetic Testing market report studies overview of market drivers, constraints, challenges and opportunities. It predicts the growth rate of the global Genetic Testing market in between the forecasted period. This research report covers the dynamics of the global Genetic Testing market with a thorough overview of the overall market growth prospects. Genetic Testing market report contain overall market size, share and growth prospect of industry.

About Genetic Testing Market:

Genetic Testing Market analysis considers sales from both equipment and consumable products. Our study also finds the sales of genetic testing in Asia, Europe, North America, and ROW. In 2019, the equipment segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing workload for performing high-throughput tests in clinical diagnostic facilities will play a significant role in the equipment segment to maintain its market position. Also, our global genetic testing market report looks at factors such as rising prevalence of genetic diseases and disorders, rising approval of advanced genetic testing products, and increasing affordability due to reduction in cost of genetic testing. However, varying regulations on genetic testing and research globally, issues related to product recalls, and lack of trained genetic professionals may hamper the growth of the genetic testing industry over the forecast period.

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14966951

Market Dynamics of Genetic Testing Market:

Driver: Rising Approval Of Advanced Genetic Testing Products

Trends: Growing Adoption Of Pharmacogenetic Testing In Reducing Adverse Drug Events

Challenges: Lack Of Trained Genetic Professionals

Rising approval of advanced genetic testing products

Commercial applications of genetic screening in human health management and the advent of whole genome sequencing have allowed vendors to offer a variety of innovative products in the global genetic testing market. The use of advanced technologies such as pharmacogenomics and companion diagnostics has helped vendors in assuring the safety of their products. Furthermore, the deployment of rapid and simplified technologies in genetic testing offers several benefits including the reduction in turnaround time, optimum resource use, and accuracy in genetic diagnosis. Thus, the rising approval of advanced genetic testing products will lead to the expansion of the global genetic testing market at a CAGR of over 12% during the forecast period.

Growing adoption of pharmacogenetic testing in reducing adverse drug events

The growing approval of new drug molecules and the rising demand for targeted therapies and personalized medicines have increased the adoption of pharmacogenomic testing by pharmaceutical companies. Pharmacogenomic testing combines the principles of pharmacology and genomics to study the response of an individual to any specific drug. The study of drug-specific responses allows pharmaceutical companies to prevent adverse drug incidence and ensure drug safety and performance during pre and post commercial stages. This development is expected to have a positive impact on the overall market growth.

Some Key Players of Genetic Testing Market Are:

To Understand How Covid-19 Impact is Covered in This Report https://www.industryresearch.co/enquiry/request-covid19/14966951

Genetic Testing Market Segmentation Analysis:

By Type:

Genetic Testing Market Report Highlights:

Genetic Testing Market Segment by Regions:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14966951

Some Points from Genetic Testing Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

Purchase this Report (Price 2500 USD for single user license) https://www.industryresearch.co/purchase/14966951

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Plastic Trunking Market Size by Future Scope 2020 | Global Industry Revenue, Share, Future Demand Status, Growth Segmentations Analysis by Regions Forecast to 2026

IoT Spending in Pharmaceutical Manufacturing Market Size 2020 | Global Trends Analysis by Growth Demand, Key Players by Share Analysis Forecast to 2025 Report by Industry Research.co

Pile Driving Equipment Market Growth Analysis by Future Trends 2020 Industry Size by Top Players, Development Plans, Business Share, Revenue and Opportunities till 2026

Garbage Disposals Market Size 2020 | Global Manufacturers with Forthcoming Developments, Regional Overview, Growth Analysis by Key Findings, Demand Status Forecast to 2025

Egg Cartons Market Size Analysis with COVID-19 Impact | Latest Trends, Development Status with Business Share, and Top Key Players Analysis Forecast to 2024

Aviation Tracking System Market Size 2020 Business Opportunities, Share, Impressive Growth Factors, Post COVID-19 Impact Analysis with Regions, Latest Technologies Forecast to 2025

LED Lighting in Poultry Farming Market Size 2020 Growth Factors, Increasing Demand Status with Top Key Players, Industry Share Forecast to 2025 Industry Research.co

RFID Tag Chips Market Growth Analysis by Trends 2020 Size of Global Key Players, Industry Share, Competitive Landscape Forecast to 2024 Industry Research.co

Distributed Fiber Optic Sensor (DFOS) Market Growth Opportunities by Evolving Technologies, Market Dynamics, Global Size, Industry Share Analysis by Key Players 2020 to 2026 Report by Industry Research.co

Hyper Converged Infrastructure Market Analysis by Revenue 2020 to 2023 Growth Rate of Key Players, Industry Share, Top Manufacturers, New Technologies and Forecast Analysis with COVID-19 Impact

Vitamin Tonics Market Size and Global Trends 2020 | Growth Factors, Competition Strategies, Revenue Analysis, Forthcoming Developments, and Business Share Forecast to 2026

Pulmonary Edema Market Size and Global Trends 2020 | Growth Factors, Competition Strategies, Revenue Analysis, Forthcoming Developments, and Business Share Forecast to 2026

Follow this link:
Genetic Testing Market by Size, Covid-19 Impact, Competitive Strategy, Worldwide Growth Insights, Regional Trends, Segmentation and Forecast to 2024 -...

Recommendation and review posted by Bethany Smith

The Direct-to-Consumer Genetic Testing Devices Market is expected to have a highly positive outlook for the next five years 2020-2026. This Research report emphasizes on key industry analysis, market size, share, growth, and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details, and latest trends in the industry.

The global Direct-to-Consumer Genetic Testing Devices market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features a comprehensive research study for high growth potential industries professional survey with market analysis. Direct-to-Consumer Genetic Testing Devices market report helps the companies to understand the market trends and future market prospective, opportunities and articulate the critical business strategies.

Request A Sample Copy Direct-to-Consumer Genetic Testing Devices Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/1046

Geographical segmentation of Direct-to-Consumer Genetic Testing Devices Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia, and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type, and application.

Direct-to-Consumer Genetic Testing Devices Market: Competitive Landscape

Leading players operating in the global Direct-to-Consumer Genetic Testing Devices market includePathway Genomics, Color Genomics, Counsyl, Inc., deCode genetics, Inc., Map My Gene, and GenePartner.

Scope of the Report

The key features of the Direct-to-Consumer Genetic Testing Devices Market report 2020-2026 are the organization, extensive amount of analysis, and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Direct-to-Consumer Genetic Testing Devices Market. The structure of keyword Market by identifying its various segments and sub-segments to help understanding the report.

keyword Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global keyword market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Direct-to-Consumer Genetic Testing Devices market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Browse more detail information about Direct-to-Consumer Genetic Testing Devices Market Report at: https://www.coherentmarketinsights.com/ongoing-insight/direct-to-consumer-genetic-testing-devices-market-1046

Important Direct-to-Consumer Genetic Testing Devices Market Data Available In This Report:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact us:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

View post:
Covid 19 Analysis On Direct-to-Consumer Genetic Testing Devices Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players |...

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China.

Myriad myChoice CDx is the industrys most clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in potentially increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors, including Lynparza (olaparib). A biomarker subgroup analysis of the PAOLA-1 Phase III trial (Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer, 2019) of Lynparza included patients with advanced ovarian cancer and homologous recombination deficient (HRD)-positive tumors as detected by the myChoice test, including those with BRCA gene mutations. The trial showed that Lynparza in combination with bevacizumab maintenance treatment improved progression-free survival to a median of 37.2 months versus 17.7 months for bevacizumab alone in patients with HRD-positive advanced ovarian cancer. Recently, the European Commission authorized use of Lynparza for the first-line maintenance treatment with bevacizumab of patients with HRD-positive advanced ovarian cancer. Lynparza is jointly developed and commercialized by AstraZeneca (LSE/STO/Nasdaq: AZN) and Merck.

As part of the expansion in Europe, Myriad will license and provide technological support to leading pathology institutes in Germany and France. Additionally, Myriad will support European customers by performing testing out of its clinical laboratory at the companys global headquarters in Salt Lake City. Also, the institutes in Europe will perform the tests with Myriads myChoice CDx PLUS assay. Myriad myChoice CDx PLUS is CE-marked in accordance with the In-Vitro Diagnostic Devices Directive (98/79/EC).

Another collaboration in China provides that Myriad will partner with Burning Rock Biotech, a leader in next generation sequencing technology for precision oncology, to provide myChoice for HRD testing in Phase III clinical studies and clinics throughout China. Myriad will provide Burning Rock with access to its proprietary myChoice technology. The partnership with Burning Rock expands global access to myChoice and positions the test as a preferred developmental companion diagnostic in this important drug development category.

These new strategic partnerships with leading companies dedicated to advancing the power of precision medicine, reinforce Myriads commitment to expanding access to genetic insights for more patients than ever before, said Nicole Lambert, president of Myriad Genetic Laboratories. Through close collaboration with innovative laboratories in Europe and with Burning Rock in China, we are bringing the clinical benefits of myChoice testing to additional markets and patients, advancing personalized treatment for patients around the world.

In August 2020, myChoice was exclusively cited and the only named commercial companion diagnostic by the American Society of Clinical Oncology in new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer. The new recommendations, based on clinical trial results, were published in the Journal of Clinical Oncology.

AboutMyriad myChoice Myriad myChoice is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The myChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). For more information, visit: https://myriad-oncology.com/mychoice-cdx/

About Myriad Genetics Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website:www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys new international collaborations on the myChoice CDx test, including offering the test to European patients, and partnering with pathology institutes in Europe and Burning Rock in China; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Jared Maxwell (801) 505-5027 jmaxwell@myriad.comInvestor Contact: Scott Gleason(801) 584-1143sgleason@myriad.com

Read the original post:
Myriad Genetics Announces Global Expansion of Myriad myChoice Tumor Testing in Europe and China - GlobeNewswire

Recommendation and review posted by Bethany Smith

The human endocrine system consists of a number of glands, which release hormones to control many different functions.

When the hormones leave the glands, they enter the bloodstream and are transported to organs and tissues in every part of the body.

The adrenal, or suprarenal, glands are located on top of the kidneys. They are divided into two regions. The right gland is triangular, and the left is crescent-shaped.

The adrenal glands secrete:

Both men and women have some androgen, but men have higher levels. Androgens control the development of characteristics associated with males, like facial hair and a deeper voice.

The hypothalamus is located just above the brain stem and below the thalamus.

This gland activates and controls involuntary body functions, including respiration, heart rate, appetite, sleep, temperature, and the circadian cycles, or daily rhythms.

The hypothalamus links the nervous system to the endocrine system via the attached pituitary gland.

The ovaries are located on either side of the uterus in females. They secrete the hormones estrogen and progesterone.

These hormones promote sexual development, fertility, and menstruation.

The testicles are located in the scrotum, below the penis in males. They secrete androgens, mainly testosterone.

Androgens control sexual development, puberty, facial hair, sexual behavior, libido, erectile function, and the formation of sperm cells.

Located in the abdomen, the pancreas is both an endocrine gland and a digestive organ.

It releases:

Diabetes and digestive issues can result if there are problems with the pancreas.

This is a small endocrine gland located deep in the brain. It secretes melatonin and helps control the bodys sleep patterns and moderate levels of reproductive hormones.

An endocrine gland attached to the hypothalamus at the base of the brain.

It is sometimes called the main endocrine master gland because it secretes hormones that regulate the functions of other glands, as well as growth and several other bodily functions.

The anterior, or front, pituitary secretes hormones that affect sexual development, thyroid function, growth, skin pigmentation, and adrenocortical function.

If the anterior pituitary is underactive, it can lead to stunted growth in childhood and underactivity in other endocrine glands.

The posterior, or rear, pituitary secretes oxytocin, a hormone that increases contractions of the uterus and antidiuretic hormone (ADH) which encourages the kidneys to reabsorb water.

The thymus is an endocrine gland located beneath the breastbone, or sternum.

T lymphocytes, a type of immune cell, mature and multiply in the thymus gland early in life. After puberty, the gland shrinks.

The thymus gland plays a role in the immune system, which protects the body against disease and infection.

A butterfly-shaped gland located just below the Adams apple in the neck, the thyroid produces hormones that play a key role in regulating blood pressure, body temperature, heart rate, metabolism, and how the body reacts to other hormones.

The thyroid gland uses iodine to create hormones.

The two main hormones it produces are thyroxine and triiodothyronine.

It also produces calcitonin, which helps strengthen bones and regulates the metabolism of calcium.

Below is a 3-D model of the endocrine system, which is fully interactive.

Explore the model using your mouse pad or touchscreen to understand more about the endocrine system.

During the first visit, the doctor will ask the patient a series of questions to help reach a diagnosis.

These might cover:

It can help to list any existing symptoms before the visit.

The endocrinologist might ask about symptoms that do not seem to be related, or that seem unnecessary.

This is because hormone levels affect so many different systems in the body that just small changes in one gland can impact parts of the body far from the site of the glands themselves.

They will check the patients heart rate and blood pressure, and look at the condition of their skin, hair, teeth, and mouth.

Blood and urine samples may be taken.

Following diagnosis, the endocrinologist will suggest a treatment plan. This will depend on which underlying condition is causing the symptoms.

Link:
Endocrinologist: Why would I visit and what can I expect?

Recommendation and review posted by Bethany Smith

by Dr. Elizabeth Lee Vliet

SARS-CoV-2 virus was virtually unknown when it hit in early 2020. COVID-19, as the disease is known, now has more than 60,000 National Library of Medicine citations, as the internet disseminates information at the speed of light. Recently President Trump was treated early for COVID-19, with rapid success.

What are the lessons learned from the scientific research?

Lesson 1: COVID-19 is not the death sentence we had at first thought. For healthy 74-year-olds who do not smoke tobacco, dont drink alcohol, and have no serious medical conditions such as heart disease, lung disease, diabetes, kidney disease, or morbid obesity, recovery rate is better than 95%.

Lesson 2: Early treatment at first sign of symptoms is critical. Thousands of frontline physicians in the US and around the world have been saying this from the beginning. Early treatment is the principle that guides almost all medical practicefrom heart disease to diabetes to cancer. In viral diseases, early treatment is critical. Patients need antiviral medicines, vitamins, minerals, known immune boosters, fresh air, and sunshine.

Studies confirm early treatment for COVID-19. In more than 130 studies compiled at c19study.com, the early-treatment studies using hydroxychloroquine (HCQ) showed a favorable effect of HCQ with other antivirals, with a median improvement of 64 percent. We accept 30-40 percent as a success with flu vaccine. Why wouldnt 64 percent improvement with antiviral medicines be considered a huge success? Even the majority of late treatment studies in very sick hospitalized patients showed around 25% improvement with HCQ.

Lesson 3: Doctors have now learned what medicines work, and when to use them. Many physicians across Americamyself included--are using a combination approach to early treatment for COVID, keeping patients at home for treatment with family and loved ones around them helping to implement the physicians recommendations.

A peer-reviewed algorithm by lead author Baylor cardiologist Peter McCullough, M.D. and colleagues from major US and Italian medical centers shows the widely available, safe medicines targeted for each stage of COVID-19 illness. Doctors already use these generic medicines day in and day out for many conditions. They now show impressive success with COVID-19.

Dr. McCulloughs team of experts recommend cheap, safe, FDA-approved medicineshydroxychloroquine (HCQ) with azithromycin or doxycycline, possibly ivermectin or colchicine, inhaled budesonide or the more potent oral prednisone, anticoagulants, supplemental zinc, vitamin C and vitamin D, and home oxygen concentrators.

With the possible exception of mechanical ventilation, almost all the treatment modalities treatment used in hospitals can be implemented at homefaster, better tailored to the individual, at lower risk of other infections common in hospitals, and at dramatically lower cost.

Lesson 4: LATE stage treatment of COVID carries a high risk of ICU admission, mechanical ventilation and death. The failed Fauci model telling patients to go home, self quarantine, do nothing, and go to the ER if they sickerexacerbated by the FDAs statements discouraging HCQ use, has caused the US COVID death rate to be in the worlds top ten.

Lesson 5: Widespread use of home therapy could prevent thousands of deaths and hospitalizations. The pathophysiological rationale and protocol published in the prestigious American Journal of Medicine gives much needed hope for physicians and patients around the world. Dr. McCullough is not just theorizing. He is actually treating COVID patients who remain in their own homes.

This is not just theory for me either. I have personally collaborated with Dr. McCullough using this home-based model of care for my own seriously ill COVID patients who live in other states. TeleHealth allows visually checking the patient, remote access to vital signs, and electronic ordering of medications and medical equipment such as oxygen concentrators when needed. In my experience, early aggressive outpatient treatment can usually be handled with oral medicines, but home health services can provide intravenous medicines if necessary. One of my seriously ill COVID patients in Virginia, a 63-year-old health care worker, is alive today and avoided hospitalization because of early treatment at home following Dr. McCulloughs algorithm.

But patients and physicians suffer as the FDA continues to erect barriers to early home-based treatment for COVID-19. FDA refuses to retract its negative statements on HCQ or release the national stockpile of HCQ donated by Big Pharma to help save American lives.

In a letter delivered August 19 to FDA Commissioner Stephen Hahn, Sen. Ron Johnson (R-Wis.), Chairman of the Senate Oversight Committee on Government Affairs and National Security, with Sen. Ted Cruz (R-Tex.) and Sen. Mike Lee (R-Utah) requested the FDAs data used to claim HCQ given within the first seven days of COVID symptoms might be harmful in outpatients. The FDAs reply deadline was August 25.

The FDA stonewalled until October 6, when the Senators finally received a response letter that completely ignored the questions asked by the Senators. FDA failed to produce any data at all that showed use of HCQ for early outpatients had no clinical effect or caused harm.

Whom is the FDA protecting by stonewalling, using a false narrative of outpatient harm with HCQthat even the FDA itself cannot support with its data? Are they preserving profits for Big Pharma with new high-cost medicines still on patentfor example, Gileads costly experimental drug remdesivir, or Regeneron, another high cost experimental drug given to President Trump?

Americans have the right to know why low-cost medicine, widely used for other conditions for decades, are suddenly too dangerous to be used for COVID-9 so people can stay at home to be treated and get well quickly.

Enormous financial conflicts exist within NIH, CDC and FDAand all receive payments from pharmaceutical companies and vaccine manufacturers, as well as income from patents on new vaccine adjuvants and processes. Dr. McCulloughs editorial, The Great Gamble of Covid-19 Vaccine Development, explained this multibillion-dollar financial incentive to preserve vaccine windfall profits in wealthy countries.

Print Dr. McCulloughs article. This can save your life. Learn your options before you get sick. Make a copy for your doctor. This entire model of care can be implemented by your local physician, in your own home, with minimal cost, and gives you the best chance of rapid recovery.

I know these doctors are right from my own experience treating patients. If you get admitted to hospital, you will likely be a prisoner with no visits from family, clergy, or the doctor of your choiceand at high risk of complications and death. For most patients, hospitalization is unnecessary.

Patients and physicians must take the initiative from the start, use the home-based methods that work, instead of trusting in FDA-promoted no-treatment standard of care, waiting in fear for a vaccine magic bullet.

(Dr. Vliet has been a leader in patient centered, individualized medical care. Since 1986, she has practiced medicine independent of insurance contracts that interfere with patient-physician relationships and decision-making. Dr. Vliet focus is medical freedom and free market approaches to healthcare. Dr. Vliet is the founder of Vive Life Center and Hormone Health Strategies with medical practices in Tucson AZ and Dallas TX, specializing in preventive and climacteric medicine with an integrated approach to evaluation and treatment of women and men with complex medical and hormonal problems from puberty to late life.)

Read this article:
There is hope and help for treating COVID-19 at home - Gasconade County Republican

Recommendation and review posted by Bethany Smith

Hanne Hoffmann, assistant professor in the College of Agriculture and Natural Resources, and her colleagues in the Hoffmann Lab, study how light regulates our physiology, affects our overall well-being and mood and induces changes in brain function. As winter approaches, Hoffmann answers questions about light and seasonal affective disorder, or SAD.

What is SAD?

Seasonal affective disorder is a type of depression that is related to changes in seasons. It usually begins with less hours of sunlight in the fall and eases in spring when days gets longer. Interestingly, a small proportion of people do experience SAD in the summer. Due to the seasonality of SAD, it is commonly known as seasonal depression. Although anyone can get SAD, women experience it four times more frequently than men. At this point, its unclear why women are more at risk for SAD than men. Since the disorder is caused by changes in day length, the further away from the equator you live, the higher the risk of experiencing it.

How many people have it?

Studies indicate that as many as 20% to 40% of people living at approximately the same latitude as Michigan experience some degree of SAD in the winter. However, this number could easily be reduced through lifestyle adaptations, including spending more time outside and using light therapy.

Hanne Hoffmann, assistant professor in the College of Agriculture and Natural Resources.

What does lack of light do to your body and how does it affect health?

Light matters because it boosts your mood and energy. To regulate your mood and physiology, light-sensing cells send light information to the brain through the optic nerve in your eye. From here, neurons in the brain further relay the light information to regulate mood and hormone release, changing physiological functions depending on the season of the year. The impact on physiological changes in response to light is more pronounced when exposed to blue and green light wavelengths than red light wavelengths. The exact mechanisms happening in the brain for light to regulate mood is poorly understood, but evidence supports that light can regulate the mood-enhancing neurotransmitter serotonin as well as the sleep-promoting hormone melatonin.

In the summer, when most people get a lot of natural light, this promotes changes in the body allowing an increased sense of well-being, more energy and good mood. In the fall, when most people spend less time outside, combined with days with less hours of sunlight, many do not get enough natural light to maintain the feeling happy brain signals, and start to feel sad. The onset of SAD is progressive and is therefore often overlooked.

Common signs of SAD include lack of energy, reduced motivation, trouble concentrating and feeling down as well as being grumpy, moody or anxious. You might eat more and gain weight. Your sleep quality often is reduced, and you might sleep more but still feel tired when you get up. To be appropriately diagnosed, you should see your primary care physician.

Will it be harder to deal with SAD this winter?

This is an unusual year with the COVID-19 pandemic causing increased isolation, more time indoors and increased stress. These are all risk factors for depression and SAD, which is supported by recent research evaluating depression in the summer of 2020 and found an increase in depression by more than three times. Due to the continued changes in lifestyle, increased work, family stressors and reduced social interactions, we can expect to see a significant increase in SAD this winter.

Does light therapy really work?

Yes, the good news is that light therapy works for almost everyone to prevent or reverse SAD.

The general rule is to imitate the natural light cycle of the outdoors: bright (blue rich) light during the day and dimmer (with little to no blue light, and more red light) in the evening. Today, there are many affordable light boxes, also known as SAD lamps, which can be purchased and used to help prevent the disorder.

To reverse SAD, start light treatment as soon as possible. The benefit of light treatment will take days to weeks to happen, so be patient. Heres how to use a light box:

Use daily if possible, but at least five days per week.

Use early after waking, preferably between 7 and 8 a.m. or during the middle of the day. These are the times of day when the body is the most sensitive to the mood-enhancing properties of light. Most importantly, just get some light.

You do not need to use the light box at the same time of day every day.

Avoid extensive use in the late afternoon, and do not use it in the evening or after sunset. In the evening, you want to avoid bright light to promote melatonin release, which will help you sleep.

Use the lightbox at least one to one and a half hours per day. This can be broken down into two or three sittings. You can use it less, 30 to 40 minutes, if you use it in the morning right after waking up.

Do you have recommendations on what to look for in a light box?

These are some general recommendations, and many different light boxes exist. The important criteria is bright intensity (light brightness is measured in lux). On average, a light box with the below criteria cost is approximately $60 to $140.

Use a light box with 10,000 lux at 12 inches or more from your face.

Some of the more expensive light box models, which cost more than $150, will allow you to be up to two feet away and still get the recommended amount of light.

Make sure the light has a UV filter to avoid the risk of retinal damage to the eyes.

Do not look straight into the light box. For example, place it at an angle next to your computer screen or on the table next to where you are reading a book. If you love cooking, hang it on the wall in the part of the kitchen where you spend the most time.

In addition to light therapy, is there anything else we can do to prevent or reduce SAD symptoms?

Yes, there are other things to combine with light therapy that will help.

Consider talk therapy. Twice a week talk therapy sessions with a friend have been shown to be effective at reducing the symptoms of SAD, and it works well in combination with light therapy.

Consider antidepressants. If you suspect you have SAD or are at risk of developing SAD, see your physician, who may prescribe antidepressants. Antidepressants are, in most cases, effective at treating SAD.

Take vitamin D. Vitamin D deficiency is very common and more pronounced in the winter due to reduced natural sunlight, and studies indicate it can improve depression. Before starting supplements, its best to have your Vitamin D levels evaluated by your primary care physician to help determine the best dosage.

Get outside regularly during the day. Natural light is a great prevention and treatment strategy for SAD.

Try to reduce your stress level in the afternoon because stress and too much light will impair your sleep.

Increasing your sleep quality by sleeping through the night and getting at least seven and a half hours, which is beneficial for your overall mental and physical well-being.

Read the original:
Ask the expert: Light, seasonal affective disorder and COVID-19 - MSUToday

Recommendation and review posted by Bethany Smith

Maintaining a good quality of life with the disease requires early detection and appropriate treatment

Let's start before prostate cancer is even detected. Maintaining a well-balanced diet, keeping one's weight in check, reducing alcohol consumption and avoiding smoking, are all key to an overall healthy lifestyle. Regular exercise, while also a part of any wellness regime, has a specific benefit for prostate health. Prostate cancer reacts strongly to steroids in the body, and regular exercise helps to stabilize steroid levels by counterbalancing the 'everyday' stresses that flood the body with adrenaline.

However, despite maintaining a healthy lifestyle, genetics also play a role that should be considered. Men who have a first-degree relative (e.g. a father or brother) with prostate cancer are twice as likely to develop the disease, and there is also a generally heightened risk if a mother or sister has been diagnosed with breast cancer.

Understanding the warning signs is key. For example, any urinary disfunction exhibited after the age of 50 should be a signal to have a clinical visit with a urologist - these specialists are very adept at detection.

Normally, a clinical exam by way of a digital rectal examination should suffice to provide everything required for an initial diagnosis. Combining this exam with a simple blood test to detect PSA (prostate-specific antigen) can confirm the diagnosis and determine the extent of tumor growth. Given the low mortality risk of prostate cancer, doctors tend to monitor the aggressivity of the tumor with frequent PSA testing and ultrasounds, etc., before undertaking specific treatment. Depending on the progression of the disease and the age of the patient, several treatments are available to maintain quality of life.

So, what does it mean to prioritize 'quality of life' or 'living better' with prostate cancer? Unfortunately, several of the treatment options have consequences that, while effective at removing the cancer, have negative impacts on the day-to-day life of a patient, including erectile dysfunction and urinary difficulties. Consequently, depending on the age of the patient and the progression of the disease, the 'eradication' of the cancer through full or partial removal of the prostate (prostatectomy) may leave a relatively young, early-stage patient with negative side effects that could last a lifetime. It could be said that the most recent 'breakthrough' in the treatment of prostate cancer is managing the medical mindset to spare patients from systematic surgery, by taking into account their day-to-day holistic quality of life and considering the full array of treatment options.

In the early stages, frequent monitoring for tumor progression using PSA testing and ultrasound may be all that doctors advise. This offers the patient a longer 'normal/functional' window before other interventions are advised. Unlike other cancers, where eradication is the immediate priority, the objective of most prostate cancer treatments is to delay the progression of the disease and offer the patient the best life possible.

In the later stages, the introduction of hormone therapy may be advised. This involves suppressing the level of testosterone on which the cancer cells feed. Steroid levels are quite important in this disease - the higher the levels, the worse the potential prognosis. So, if testosterone levels are very high, reducing them through treatment may have a positive patient impact. This treatment is effective at stopping growth and 'choking off' the cancer cells and offers the patient an ongoing good quality of life. Depending upon the extent of such treatment, which at the extreme includes full blockage of testosterone production (temporary chemical castration), there will be an impact on libido and erectile function, but neither side effect is permanent and will only exist during the period of treatment. This offers a patient with advanced disease windows of 'normal life' between treatments. One lasting side effect of hormone suppression therapy is a reduction in BMD (bone mass density), known as osteoporosis, often seen in women during menopause, yet this too is treatable.

In cases where the cancer has not spread beyond the prostate, or has spread only slightly, radiation therapy is quite effective at targeting and killing cancer cells. While a long-term side effect of this therapy is erectile disfunction, the impact is not immediate, and the patient can continue to have years of normal sexual function.

The debate on removing the prostate (prostatectomy)versuspreserving the organ function stands as a major issue that is decided patient by patient, depending on the prognosis of the disease. Thanks to advances in robotic surgery, the procedure is now more precise, which reduces the risk of erectile and urologic disfunction. Other treatments such as radiotherapy may also be advised, when applicable to the patient's level of cancer and taking into account the objective of preserving a 'good life' with the disease.

Insurance providers likewise need to take into account all the treatment options, as well as the general prognosis of a normal life expectancy in prostate cancer patients. The insured will be more likely to file claims related to reduced earning capacity due to working less, increased treatment expenses, and so forth. This is not, in most cases, a serious condition impacting life insurance claims.

In conclusion, given that most diagnosed prostate cancer patients will have a normal life expectancy, both the patient and the treating physician need to focus on how well the patient can live his life. Men need to pay attention to potential signals and visit their urologist if symptoms present themselves, especially after the age of 50. If a prostate cancer diagnosis is confirmed, it is important that the 'stress' of the word 'cancer' be tempered against what is likely to be a long life with the disease rather than a life cut short because of it.

Disclaimer

SCOR SE published this content on 19 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 November 2020 11:54:03 UTC

See more here:
Scor : Prostate Cancer it's more about living well with the disease than the risk of dying from it - Marketscreener.com

Recommendation and review posted by Bethany Smith

Natural vaginal lubrication is largely driven by the hormone estrogen and plays a crucial role in both sexual intercourse and vaginal health. When estrogen levels are low, it can cause the vaginal tissue to become thin, fragile, and dry making sex painful.

You can use store-bought lube to help with vaginal dryness, however, some lubes can actually pull natural moisture and worsen dryness. So, it's important to look for lubes that promote vaginal hydration.

Another option is vitamins and supplements that can help increase female lubrication naturally by boosting estrogen levels. But keep in mind that you should always consult a doctor before beginning any vitamin or supplement regimen to avoid dangerously high doses.

Here's what you need to know about vaginal dryness and how to boost your body's natural ability to self-lubricate.

People of all age groups can experience vaginal dryness, but it is more common in those who are menopausal. Other causes of vaginal dryness include:

Vitamin A: This vitamin is important in the development of mucous membranes, which include the lining of the vagina. "It is helpful in terms of moisture and collagen production," says Anita Sadaty, MD, attending physician in obstetrics and gynecology at Northwell Health System in New York.

Vitamin A can be taken orally, she says, but should not be taken in excess. "If vitamin A becomes extremely high there can be liver injury, but it's honestly pretty hard to overdose."

Vitamin B: Vaginal secretionscan be altered by both hormonal and dietary factors. Proper immune function is important when it comes to vaginal health, and vitamin B complex a supplement that includes all eight types of vitamin B boosts immune function.

It can be taken as a supplement or absorbed through food sources including poultry, fish, potatoes, and bananas. But too much can be dangerous. It can lead to a lack of muscle control, stomach issues, and painful lesions.

Beta-carotene: Beta-carotene is a provitamin, meaning your body uses it to make another vitamin, in this case, vitamin A. As stated above, vitamin A helps fend off vaginal dryness.

Beta-carotene is found in foods includingcarrots, dark-green leafy vegetables, sweet potatoes, broccoli, cantaloupe, and winter squash. Though it is not toxic in high doses, too much can cause the skin to take on a yellow-orange hue among other side effects.

Omega-3 fatty acids: "In general, essential fatty acids will help improve the architecture of the vaginal mucosa," Sadaty says. A 2012 study found omega-3 to significantly reduce vaginal dryness for six months among postmenopausal breast cancer survivors with vaginal atrophy(atrophic vaginitis), which is a thinning, drying, and inflammation of the vaginal walls.

Sadaty says although there have been concerns that high levels of omega-3s may lead to blood-thinning or excess bleeding, research does not support that claim.

Vitamin E: This is another vitamin that can help promote vaginal lubrication. A small 2016 study of 52 postmenopausal women showed vitamin E vaginal suppositories helped the majority of subjects with symptoms of vaginal atrophy, including dryness. Vitamin E can also be ingested from various foods, including plant-based oils, nuts, seeds, fruits, and vegetables.

"Foods like pumpkin and sunflower seeds are all good for dryness," Sadaty says. When sourced naturally through food, vitamin E carries no risk. But in supplement form, high doses of vitamin E might increase the risk of bleeding by interfering with the blood's ability to clot. This could potentially lead to a hemorrhagic stroke, or bleeding in the brain, though this is rare.

Vaginal DHEA: Your body produces the hormone dehydroepiandrosterone (DHEA), which in turn, helps produce other hormones including estrogen. DHEA levels peak in early adulthood and decrease with age. For vaginal dryness, a doctor may prescribe a synthetic version of DHEA as an oral treatment or a topical cream.

A 2016 study spanning 12 weeks found vaginal secretions improved in participants by 86% to 121% over the placebo effect. However, DHEA treatments may have some risks, including an increase in the risk of hormone-sensitive cancers, such as breast and ovarian cancers. It should also be avoided if you have high cholesterol.

Low-dose estrogen/estrogen cream: There are two types of estrogen treatments for vaginal dryness:

Hyaluronic acid: Hyaluronic acid is a molecule that exists naturally in your skin and is key to keeping it moist. However, you can also get hyaluronic acid as a topical gel, which multiple studies have found can help vaginal dryness in postmenopausal women.

One of the most important factors in balancing your hormones is a low level of stress, Sadaty says. Research is still limited, but stress, anxiety, and depression are thought to make vaginal dryness worse.

To combat this, Sadaty recommends the "big three": exercise, balanced diet, and sufficient sleep. Research shows exercise plays a key role in happiness and emotional resilience. Studies have also found that sleep not only reduces stress by recharging and restoring the body but leads to greater life satisfaction.

And while a particular diet can be an important stress-management tool, there are also foods rich in the previously mentioned vitamins that can drastically reduce dryness, including vegetables, nuts, seeds, and healthy fats.

If you are experiencing vaginal dryness, it should be dealt with as soon as possible, Sadaty says. Seek out medical support if dryness is persistent or painful.

"If you allow dryness and vaginal thinning to go on long enough, sometimes it's harder to fix it," Sadaty says. "At some point, it's difficult to restore the anatomy."

Vaginal lubrication is a key aspect of overall health and sexual satisfaction. Those who have issues with it may have estrogen deficiencies, which can be treated with vitamins, supplements, hormone treatments, and creams.

People who experience vaginal lubrication issues should seek medical counsel as soon as possible. Always consult a medical professional before taking supplements or medications.

Continue reading here:
How to boost vaginal lubrication naturally, according to an OB-GYN - Insider - INSIDER

Recommendation and review posted by Bethany Smith

USA Gymnastics policy changes allowing trans athletes to compete in disciplines aligning with gender identity without sex reassignment surgery or hormone treatment is a disgusting violation of womens rights to appease a minority.

In a familiar tale of the perennial battle to establish super-inclusive safe spaces at the expense of logic orthe safety and rights of others, USA Gymnastics (USAG) on Tuesday pledged to remove surgical sex reassignment, legal gender recognition, and hormone therapy requirements as requirements for transgender athletes to compete in disciplines they consider align with their gender identity.

The new policy changes effectively gives any athlete born male but identifying as a transgender woman free reign to campaign alongside women without having to forego the inconvenience of anything that might give their claim to be a member of the opposite sex any shred of credibility.

Also on rt.comFeminists infuriated but gay gamers rejoice at Dua Lipa as FIFAs cheap attempt to sell sex takes unexpected turn

And just why has USAG decided to become part ofthe woke mob inclusive indoctrination process? You guessed it: feelings.

The emotional and psychological safety of transgender gymnasts or of anyone who might be offended at medical procedures, legal documents, logic or, heaven forbid, common sense, was ludicriously equated to the physical, emotional and psychological safety of other gymnasts by USAG CEO Li Li Leung in a statement released announcing the policy changes.

Our top priority is and must always be the safety of our athletes, including their emotional and psychological safety, Leung babbled in the press release. Inclusivity plays an important role in creating safe and welcoming environments for our community members, and this policy will help ensure athletes who identify as transgender or non-binary feel at home in our sport.

Leung may attempt to dress the matter up as implementing one big, cosy, marshmellow-walled haven impenetrable by the voice of reason for transgender gymnasts, but in reality, the announcement is nothing more than gender politics point-scoring to play up to the perpetually-offended progressive movement.

A closer look reveals that the timing of the USA Gymnastics woke faux-pas flex press release on Wednesday came slap bang in the middle of Transgender Awareness Week which, for those notaware, is typically celebrated in the second week of November.

Only USAG arent definitely unaware that their cuddling up to the endlessly principled teachings of the progressive gospel isnt safe, but rather a serious violation of the rights and dignity of the women and young girls in their care.

The full and frankly mind-boggling manifesto reads that USAG intends to promote an inclusive environment for athletes of all gender identities, while protecting the privacy of trans and non-binary athletes.

Protecting privacy!? Has it not occurred to USAG that not only will female gymnasts be forced to welcome a legally-recognized male into the team in the name of inclusivity, but the new policy would potentiallyexpose them to contact with a gymnast with the physical and hormonal attributes of a male in changing rooms, when rooming in hotels, or in showers, whether they like it or not, seriously compromising their privacy and dignity.

And for what? So a transgender gymnast who couldnt be bothered to go through paperwork or muster the effort to undergo a medical procedure to at least adequately fit into a leotard can feel safe and included at the expense of the feelings ofthose around them?

Is compromising the comfort and safety of young female gymnasts really acceptable procedure for an institution still reeling from one of the largest sexual abuse scandals in sporting history?

READ MORE: Scandal-hit USA Gymnastics chief to resign in the wake of horrific events of Nassar sexual abuse

In 2018, USAG filed forbankrupcy owing in part toa stream of lawsuits targetingthe organizations alleged negligence over the sexual abuse of dozens of national team members committed by disgraced former team physician and convicted pedophile Larry Nassar, some claiming the organization attempted to cover up years of serious assaultsand encouraged or coerced his victims to remain silent on their suffering.

Nassar, who servedan 18-year tenure as USAGnational medical coordinator from 1996 to 2014, was sentenced to 175 years in jail after being found guilty on numerous child sex charges dating back to 1992.

It is effortlessly ironic that USAG should take a course of action to create safe spaces for the gymnasts under their care by allowing practically all of themto be further exposed to contemporaries legally and scientifically recognized as men.

In gymnastic eventswherephysical strengthplays a significant role in the chances of success, afemale gymnast could theoretically dedicate her entire lifeto the sportonly to be pipped at the post for a place on the podium by someone significantly stronger, but who just fancied competing in that discipline, and whose word were obliged to take so as not to hurt anyones feelings other than the poor girl prevented from achieving her dreams because of strong-arm inclusivity tactics. How veryprogressive.

Such arbitrary rule making,which USAGvaguely claims isbased on current medical science and consistent with unnamed anti-discrimination legislation, despite not providing any further evidence, should be stamped out before the spurious spread of ultra-inclusivity affects other sports where womens records and achievementscould potentially be wiped out and its competitors seriously hurt by the inclusion of transgender athletes benefitting from hormonal and physical advantages over their peers.

READ MORE: Who thought Dua Lipa in FIFA was a good idea?! Gamers red-faced as pop star GROPED by players during goal celebrations

Perhaps the most laughable line of the entire shambles of a statement came fromKim Kranz, USAGsChief of Athlete Wellness, when trying to explain theircommitment to help create an inclusive environment within the sport.

Everyone should have the opportunity to participate in gymnastics with the knowledge that they will be safe and have their dignity respected, Kranz claimed.

It seems USAGs respect for dignity, safety and comfort is a luxury afforded only to thosethat campaign to be accepted and treated just as everyone else, but whose plan to achieve such is by beingtreated as an exception, all at the expense of the rights of the very young girls and women they purport to protect.

By Danny Armstrong

Link:
USA Gymnastics' 'safe space' policy to allow trans athletes to compete WITHOUT surgery is disgusting violation of women's rights NY Pilot Sport News...

Recommendation and review posted by Bethany Smith

Community Cord Blood Banking, a stem cell banking initiative introduced by LifeCell in 2017, has helped save the life of a seven-year-old girl from Nashik in Maharashtra who was suffering from aplastic anaemia, a rare and serious blood disorder.

In a major breakthrough, a team of senior doctors from LOTUS Institute of Haematology, Oncology and Bone Marrow Transplantation, recently conducted Indias first dual cord blood transplant through an unrelated donor using Community Stem Cell Banking. People familiar with the development said the transplant was challenging because no apt bone marrow donors were available and the cost of retrieval of matching units from public cord blood banks would have been high.

The girls parents, as members of LifeCell Community Bank, placed a request for two matching cord blood units after the childs sibling was found to be only a 50% (4/8) match. Two high-quality matches (7/8) were found in the registry, which fulfilled the requirement for umbilical cord blood transplantation. The parents could withdraw the matched units at no extra expense, which would have cost around 45 lakh per unit.

Mayur Abhaya, MD, LifeCell International said, The purpose of Community Cord Blood Banking is to ensure easy and rapid access to stem cells for every Indian without the hurdles of public and private banking models. While stem cells from the umbilical cord blood can be procured from global public banks, the probability of finding a match for a patient of Indian origin is less than 10% because of the low inventory of available units plus the big issue of donor dropouts.

Mr. Abhaya said, Luckily, since the family was a part of LifeCells community banking programme, they could gain quick, free access to the huge inventory of over 50,000 qualified and consented units available at LifeCell, which provides greater than 97% probability of finding a match.

In majority of blood-related disorders treatable by transplants, patients own stem cells are not suitable. Hence, the best donor is a close family member, usually a sibling. However, in this case, there was only a 50% match with the sibling, thus needing a match from an unrelated donor, LifeCell said in a statement. It said while a regular stem cell transplant requires a dose of 25 million cells per kg of the patients weight, for aplastic anaemia, the recommended minimum dose is 40 million cells per kg, which is not easy to find.

The community banking model made it possible and the child received a timely transplant with an encouraging prognosis. Just 18 days after the transplant, white blood cells were completely engrafted, and platelets and red blood cell production also increased drastically, the statement added.

Dr. Pritesh Junagade, director, LOTUS Hospital, expressed surprise that the retrieval process for two cord blood units was smooth and at no additional cost to the patient as compared to other banking models.

Tasneem Bohari, the childs father, said: It was two years ago that my daughter was diagnosed with aplastic anaemia. At the time of diagnosis, the doctors had suggested she would need a stem cell transplant eventually and it would be the best possible treatment in the future.

The family did research and made enquiries about which stem cell bank to opt for as they were expecting their second child. It was during this time that their friends and relatives suggested LifeCell to them. Their doctor also suggested that they could go ahead and preserve their babys stem cell with LifeCell.

At the time of preservation, we didnt have much idea about Community Stem Cell Banking and its benefits, but today we are happy to associate with LifeCell, who have helped my daughter lead a quality life through cord blood transplant, Mr. Bohari said.

Community Cord Blood Banking allows sharing of preserved umbilical cord stem cells from a common pool amongst the members of the community. The model offers greater and easier access to donor stem cells, unlimited retrievals at the cost of one enrolment, and a higher probability for finding a close match for potentially life-saving treatments.

This facility ensures complete protection to the child, siblings, parents, and maternal and paternal grandparents from more than 80 disorders treatable by stem cells.

See more here:
Community Cord Blood Banking saves life of child with aplastic anaemia - The Hindu

Recommendation and review posted by Bethany Smith

Stem cells found in the lungs can be redirected to the heart using a new inhaled antibody therapy to help boost healing following a heart attack.

Image credit: Jesse Orrico on Unsplash

Cardiovascular diseases are one of the leading causes of death globally. Medical advancements have lowered a persons risk of dying from an episode, but cell death and scar tissue that form afterward drastically increase the risk of eventual heart failure.

Stem cell therapy is a promising strategy used to help minimize long-term damage by regenerating new, healthy heart cells at damaged sites. However, their clinical application is hampered by poor cell engraftment, which comes with trying to grow new cells on a constantly moving organ.

Solutions to this have been proposed in the past, such as using durable patches to help the cells adhere to the heart surface, but a team of researchers from North Carolina State University propose that redirecting easy-to-access stem cells already found in the body could help spur repair in an injured heart.

Stem cells have become [] important for cardiomyocyte regeneration over the last two decades, wrote the team in their paper published in Advanced Science. In fact, as [part of] the bodys own repair mechanism, endogenous stem cells from the bone marrow are recruited into the heart. The issue, they point out, is that these stem cells lack the ability to properly target the heart, which hinders their ability to accumulate where they are needed.

In previous studies, the team demonstrated that heart attack biomarkers can be used to guide infused or endogenous stem cells to the site of cardiac injury. They also took advantage of cells called platelets, which help form blood clots and have an exceptional ability to target and accumulate in injured tissue.

By taking advantage of the injuryhoming ability of platelets, we can target stem cells to the [damaged] area, said the authors. [However], this strategy has a caveat: most of the bodys endogenous stem cells are produced in the bone marrow, and these cells are difficult to access.

The lung has recently been recognized as a site where both stem cells and navigator cells, such as platelets, are found in high concentrations. The team therefore sought to develop a strategy to link those two types of cells to provide an in-house treatment for repairing damaged cardiac tissue following a heart attack.

In this way, platelets can piggyback on stem cells found in the lungs called hematopoietic stem cells (HSCs) and bring them to the damaged site for repair, they said. To do this, they designed what is called a bispecific antibody, which is an artificial protein that can simultaneously bind to two different types of molecules. They are commonly used in treating cancers and different autoimmune diseases, but in the current study, the researchers used them to bind HSCs as well as platelets, to help the stem cells accumulate where they are needed.

An interesting and advantageous aspect of this strategy is the fact that the bispecific antibodies can be delivered through inhalation since their desired location is the lungs. Unlike previous strategies, this provides a safe, non-invansive, and convenient way of administration.

In the study, the team tested whether the inhaled antibodies could effectively link HSCs with platelets and redirect them to the injured heart, and bench-marked this route of administration against an intravenous infusion. It was found that the antibody therapy effectively conjoined HSCs and platelets, and the redirected stem cells helped promote repair and minimized inflammation at the site of injury, which led to increased cardiac function compared to controls. In addition, inhalation of the platelet-antibody therapy was found to be more efficient and specific than the intravenous route.

While there are limitations that still need to be overcome before this can move into clinical trials, this work demonstrates an innovative and easy approach to help boost heart healing and limit the long-term damage of heart attacks. The team is hopeful that this work can be used as a jumping point to help bring this type of treatment closer to clinical application.

Reference: Mengrui Liu, et al. Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury. Advanced Science (2020). DOI: 10.1002/advs.202002127

Read more from the original source:
Leveraging the lung's biogenesis to repair the heart - Advanced Science News

Recommendation and review posted by Bethany Smith

During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, professor of Oncology, director, Bone Marrow Transplant and Immune Cellular Therapy at Sidney Kimmel Cancer Center, at the Thomas Jefferson University Hospital, discussed the case of a 48-year-old male patient with acute graft-versus-host-disease (GVHD).

Targeted Oncology: For a patient such as this, what is the risk of developing acute (GVHD) following transplant?

GERGIS: The list of risk factors for GVHD is huge: donor HLA [human leukocyte antigen] disparities that are major/minor, sex matching, donor parity, donor age, blood typewhile its controversialdonor CMV seropositivity, gene polymorphism, and stemcell graft source. Obviously, peripheral mobilized stem cells have more T cells than bone marrow. Other factors include graft composition, the higher CD34 the higher lymphocytes, and conditioning intensities. There are a bunch of factors here, at least for our patient, who had a MAC. The fact that his donor is a multirisk, 50-year-old woman and a MUD [infers] similar higher risk.

How quickly do you determine whether a patient is steroid refractory or steroid dependent?

Basically, steroid refractoriness or resistance versus dependence versus intolerance [can be determined in] as early as 3 days. If there is progression of the grade of GVHD, this is considered steroid refractory. If by 4 weeks it does not go to grade 0, its considered refractory. However, I disagree with the 28-day [timeline]. I think its a long time to wait. Usually, I look at 2 weeks.

This has been the consensus among many of us. I think the trials REACH-1 [NCT02953678] and REACH-2 [NCT02435433] looked at 28 days; but if you go to the 2 papers, most responses took place in 7 to 14 days. Again, this is in the second-line setting.

Ive been doing this for 15 years. Ive been through most of this; so many lines [of therapy and] so many heartbreaks. I teach my fellows to look at any [research] paper in second-line GVHDthe overall response rate is 30%. Ive done it with MMF [mycophenolate mofetil], sirolimus [Rapamune], infliximab [Remicade], ATG [antithymocyte globulin], cyclophosphamide, Ontak [denileukin diftitox], and mesenchymal stem cells and overall response rate is 30%.

Which data support the use of ruxolitinib (Jakafi) in patients who are steroid refractory?

Based on a small trial of 49 patients, a phase 2 trial [INCB 18424-271; NCT02953678], ruxolitinib was approved as a second-line therapy for patients with acute steroid-refractory GVHD.1

Review the details of the REACH-2 trial.

The REACH-2 trial data were just published in 2020. Ruxolitinib was approved based on a small trial of 49 patients with steroid-refractory acute GVHD. They enrolled 70 but only 49 were available for efficacy. Obviously, it was a pilot phase 2 with no comparative arm, and the response rates across the board were [somewhere in the range of] 50% or so by day 28.

Then they were asked to run a phase 3 trial comparing ruxolitinib at 10 mg twice daily versus best available care. The best available care goes through the list that I just mentioned, including photopheresis, ATG, and others. After 4 weeks, patients who were not responders on the best available care were allowed to cross over to ruxolitinib.

By day 28, the responders on the ruxolitinib composed 60% of the cohort versus 40% on the control arm with a P value of less than .001. The durability of response at 8 weeks was 40% versus 20% [odds ratio, 2.38; 95% CI, 1.43 to 3.94; P < .001].

This tell us that ruxolitinib works in this group, that it does not work that great in one-third of patients who lose their response at 8 weeks, and that its just better than anything else [thats available]. A good thing about the ruxolitinib arm is that the response duration was much longer than best available treatment, as illustrated by the Kaplan-Meier curve for response duration.

Failure-free survival [in this trial] was 5.0 months versus 1.0 month [HR, 0.46; 95% CI, 0.35-0.60].

Do you apply this therapy to any of your patients?

We have a patient [at my institution] who has steroid-refractory GVHD. Last Friday in our weekly meeting, we were discussing his [case]. He has lower GI [gastrointestinal] GVHDgrade IV, steroid-refractory, as bad as it getsand I said lets start him on ruxolitinib. One of my colleagues said it doesnt work well in the lower GI. I asked the organizers to pull [data] from the supplemental figures on the New England Journal of Medicine paper of REACH-2 [indicating that these patients did have a benefit with ruxolitinib].2

REFERENCES:

1. FDA approves ruxolitinib for acute graft-versus-host disease. FDA. May 24, 2019. Accessed October 10, 2020. https://bit.ly/2SMU7I8

2. Zeiser R, von Bubnoff N, Butler J, et al; REACH2 Trial Group. Ruxolitinib for glucocorticoid- refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. doi: 10.1056/NEJMoa1917635

Continued here:
Ruxolitinib for Acute Graft-vs-Host Disease Improves Outcomes in the Second Line - Targeted Oncology

Recommendation and review posted by Bethany Smith

Egg cells harvested from Mauritian cynomolgus macaques (top left) were fertilized (top right) and injected with CRISPR gene editing materials to insert a genetic mutation that cured two men of HIV in the last decade. The growing embryos (developing in the bottom images), if carried to maturity by surrogates, will help researchers study the mutation as a potential treatment for HIV. Courtesy of Golos and Slukvin labs

A gene that cured a man of HIV a decade ago has been successfully added to developing monkey embryos in an effort to study more potential treatments for the disease.

Timothy Brown, known for years as the Berlin Patient, received a transplant of bone marrow stem cells in 2007 to treat leukemia. The cells came from a donor with a rare genetic mutation that left the surfaces of their white blood cells without a protein called CCR5. When Browns immune system was wiped out and replaced by the donated cells, his new immune systems cells carried the altered gene.

This mutation cuts a chunk out of the genome so that it loses a functional gene, CCR5, that is a co-receptor for HIV, says Ted Golos, a University of WisconsinMadison reproductive scientist and professor of comparative biosciences and obstetrics and gynecology. Without CCR5, the virus cant attach to and enter cells to make more HIV. So, in Timothy Browns case, his infection was eliminated.

In 2019, a second cancer patient Adam Castillejo, initially identified as the London patient was cleared of his HIV by a stem cell transplant conferring the same mutation.

Thats very exciting, and there have been some follow up studies. But its been complicated, to say the least, Golos says.

Between the two transplants came a more infamous application of the mutation, when in 2018 Chinese biophysicist He Jiankui announced he had used the DNA-editing tool CRISPR to write the mutation into the DNA of a pair of human embryos. His work drew criticism from scientists concerned with the ethics of altering genes that can be passed down to human offspring, and he was jailed by the Chinese government for fraud.

The promise of the CCR5 mutation remains, but not without further study. The mutation occurs naturally in fewer than 1 percent of people, suggesting that it may not be associated only with positive health outcomes. An animal model for research can help answer open questions.

Given interest in moving forward gene-editing technologies for correcting genetic diseases, preclinical studies of embryo editing in nonhuman primates are very critical, says stem cell researcher Igor Slukvin, a UWMadison professor of pathology and laboratory medicine.

Golos, Slukvin and colleagues at UWMadisons Wisconsin National Primate Research Center and schools of Veterinary Medicine and Medicine and Public Health employed CRISPR to edit the DNA in newly fertilized embryos of cynomolgus macaque monkeys. They published their work recently in the journal Scientific Reports.

Slukvins lab had already established a method for slicing the CCR5-producing gene out of the DNA in human pluripotent stem cells, which can be used to generate immune cells resistant to HIV.

We used that same targeting construct that we already knew worked in cells, and delivered it to one-cell fertilized embryos, says Jenna Kropp Schmidt, a Wisconsin National Primate Research Center scientist. The thought is that if you make the genetic edit in the early embryo that it should propagate through all the cells as the embryo grows.

Primate Center scientist Nick Strelchenko found that as much as one-third of the time the gene edits successfully deleted the sections of DNA in CRISPRs crosshairs base pairs in both of the two copies of the CCR5 gene on a chromosome and were carried on into new cells as the embryos grew.

The goal now is to transfer these embryos into surrogates to produce live offspring who carry the mutation, Schmidt says.

Cynomolgus macaques are native to Southeast Asia, but a group of the monkeys has lived in isolation on the Indian Ocean island of Mauritius for about 500 years. Because the entire Mauritian monkey line descends from a small handful of founders, they have just seven variations of the major histocompatibility complex, the group of genes that must be matched between donor and recipient for a successful bone marrow transplant. There are hundreds of MHC variations in humans.

With MHC-matched monkeys carrying the CCR5 mutation, the researchers would have a reliable way to study how successful the transplants are against the simian immunodeficiency virus, which works in monkeys just like HIV does in humans.

Anti-retroviral drugs have really positively changed the expectation for HIV infection, but in some patients, they may not be as effective. And theyre certainly not without long-term consequences, says Golos, whose work is funded by the National Institutes of Health. So, this is potentially an alternative approach, which also allows us to expand our understanding of the immune system and how it might protect people from HIV infection.

The animal model could lead to the development of gene-edited human hematopoietic stem cells the type that work in bone marrow to produce many kinds of blood cells that Slukvin and Golos say could be used as an off-the-shelf treatment for HIV infection.

This research was supported by grants from the National Institutes of Health (R24OD021322, P51OD011106, K99 HD099154-01, RR15459-01 and RR020141-01).

Read the rest here:
Gene-edited monkey embryos give researchers new way to study HIV cure - University of Wisconsin-Madison

Recommendation and review posted by Bethany Smith

The global Hematopoietic Stem Cell Transplantation (HSCT) market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Hematopoietic Stem Cell Transplantation (HSCT) market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Hematopoietic Stem Cell Transplantation (HSCT) market. The authors of the report profile leading companies of the global Hematopoietic Stem Cell Transplantation (HSCT) market, such as Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Hematopoietic Stem Cell Transplantation (HSCT) market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Hematopoietic Stem Cell Transplantation (HSCT) market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Hematopoietic Stem Cell Transplantation (HSCT) market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Hematopoietic Stem Cell Transplantation (HSCT) industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Hematopoietic Stem Cell Transplantation (HSCT) market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2244866/global-hematopoietic-stem-cell-transplantation-hsct-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Hematopoietic Stem Cell Transplantation (HSCT) market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Hematopoietic Stem Cell Transplantation (HSCT) market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Hematopoietic Stem Cell Transplantation (HSCT) market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market by Product: , Allogeneic, Autologous

Global Hematopoietic Stem Cell Transplantation (HSCT) Market by Application: Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)

The report also focuses on the geographical analysis of the global Hematopoietic Stem Cell Transplantation (HSCT) market, where important regions and countries are studied in great detail.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2244866/global-hematopoietic-stem-cell-transplantation-hsct-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/2f1b9ae8698531348ef5b10dfb21f331,0,1,global-hematopoietic-stem-cell-transplantation-hsct-market

Table Of Contents:

1 Market Overview of Hematopoietic Stem Cell Transplantation (HSCT)1.1 Hematopoietic Stem Cell Transplantation (HSCT) Market Overview1.1.1 Hematopoietic Stem Cell Transplantation (HSCT) Product Scope1.1.2 Market Status and Outlook1.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Region (2015-2026)1.4 Global Hematopoietic Stem Cell Transplantation (HSCT) Historic Market Size by Region (2015-2020)1.5 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size Forecast by Region (2021-2026)1.6 Key Regions, Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026)1.6.1 North America Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026)1.6.2 Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026)1.6.4 Latin America Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Hematopoietic Stem Cell Transplantation (HSCT) Market Size YoY Growth (2015-2026) 2 Hematopoietic Stem Cell Transplantation (HSCT) Market Overview by Type2.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type: 2015 VS 2020 VS 20262.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Historic Market Size by Type (2015-2020)2.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Forecasted Market Size by Type (2021-2026)2.4 Allogeneic2.5 Autologous 3 Hematopoietic Stem Cell Transplantation (HSCT) Market Overview by Application3.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Application: 2015 VS 2020 VS 20263.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Historic Market Size by Application (2015-2020)3.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Forecasted Market Size by Application (2021-2026)3.4 Peripheral Blood Stem Cells Transplant (PBSCT)3.5 Bone Marrow Transplant (BMT)3.6 Cord Blood Transplant (CBT) 4 Global Hematopoietic Stem Cell Transplantation (HSCT) Competition Analysis by Players4.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematopoietic Stem Cell Transplantation (HSCT) as of 2019)4.3 Date of Key Manufacturers Enter into Hematopoietic Stem Cell Transplantation (HSCT) Market4.4 Global Top Players Hematopoietic Stem Cell Transplantation (HSCT) Headquarters and Area Served4.5 Key Players Hematopoietic Stem Cell Transplantation (HSCT) Product Solution and Service4.6 Competitive Status4.6.1 Hematopoietic Stem Cell Transplantation (HSCT) Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Regen Biopharma Inc5.1.1 Regen Biopharma Inc Profile5.1.2 Regen Biopharma Inc Main Business5.1.3 Regen Biopharma Inc Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.1.4 Regen Biopharma Inc Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.1.5 Regen Biopharma Inc Recent Developments5.2 China Cord Blood Corp5.2.1 China Cord Blood Corp Profile5.2.2 China Cord Blood Corp Main Business5.2.3 China Cord Blood Corp Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.2.4 China Cord Blood Corp Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.2.5 China Cord Blood Corp Recent Developments5.3 CBR Systems Inc5.5.1 CBR Systems Inc Profile5.3.2 CBR Systems Inc Main Business5.3.3 CBR Systems Inc Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.3.4 CBR Systems Inc Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.3.5 Escape Therapeutics Inc Recent Developments5.4 Escape Therapeutics Inc5.4.1 Escape Therapeutics Inc Profile5.4.2 Escape Therapeutics Inc Main Business5.4.3 Escape Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.4.4 Escape Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.4.5 Escape Therapeutics Inc Recent Developments5.5 Cryo-Save AG5.5.1 Cryo-Save AG Profile5.5.2 Cryo-Save AG Main Business5.5.3 Cryo-Save AG Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.5.4 Cryo-Save AG Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.5.5 Cryo-Save AG Recent Developments5.6 Lonza Group Ltd5.6.1 Lonza Group Ltd Profile5.6.2 Lonza Group Ltd Main Business5.6.3 Lonza Group Ltd Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.6.4 Lonza Group Ltd Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.6.5 Lonza Group Ltd Recent Developments5.7 Pluristem Therapeutics Inc5.7.1 Pluristem Therapeutics Inc Profile5.7.2 Pluristem Therapeutics Inc Main Business5.7.3 Pluristem Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.7.4 Pluristem Therapeutics Inc Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.7.5 Pluristem Therapeutics Inc Recent Developments5.8 ViaCord Inc5.8.1 ViaCord Inc Profile5.8.2 ViaCord Inc Main Business5.8.3 ViaCord Inc Hematopoietic Stem Cell Transplantation (HSCT) Products, Services and Solutions5.8.4 ViaCord Inc Hematopoietic Stem Cell Transplantation (HSCT) Revenue (US$ Million) & (2015-2020)5.8.5 ViaCord Inc Recent Developments 6 North America6.1 North America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Hematopoietic Stem Cell Transplantation (HSCT) Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more:
Hematopoietic Stem Cell Transplantation (HSCT) Market by Product Type, End User and by Region-Trends and Forecast to 2026|China Cord Blood Corp, CBR...

Recommendation and review posted by Bethany Smith

Chamber Member Update

Boca Raton, FL, November 17 Every three minutes a person in the United States is diagnosed with a blood disease such as leukemia, immunodeficiencies and sickle cell. To deliver cutting-edge, lifesaving therapy services for stem cell transplantations and improve patient outcomes, the Gift of Life Marrow Registry has announced the newly opened the Gift of Life Center for Cell and Gene Therapy.

Located at Gift of Lifesheadquarters in Boca Raton, Fla., theCenter will provide transplant physicians, researchers, and cell and gene therapy developers with the donor cell products they need to help more patients than ever before. One of the Centers signature services will be a biobank of off-the-shelf, on-demand cell therapy products available for transplantation, as well as those for engineering and ethical research. The inventory will be comprised of products collected from super donors with high frequency genetic characteristics sourced from the Gift of Life Marrow Registry. These cells will be tested, processed and cryopreserved by the Centers cellular therapy laboratory.

Another specialty service is the Centers innovation program, which will collaborate with world-renowned South Florida research institutions to improve transplant outcomes, develop processes for cell expansion and much more.

While many advancements have been made in stem cell treatments for those with blood diseases, there are still critical barriers that can impeded success, said Gift of Life CEO and Founder Jay Feinberg.

The only registry in the world started and run by a transplant survivor, Gift of Life has pioneered key innovations in the stem cell transplantation and donation process. Last April, the organization become the first registry to operate an in-house stem cell collection center that has not only helped to bring stem cell donors to collection faster, but also greatly improves the experience for donors. Gift of life is also the first registry to use buccal cheek swabs at recruitment drives instead of blood draws and the first to do mobile registration, including the creation of a smart phone app to register individuals quickly and effectively.

Gift of Lifes overarching mission isto democratize celltherapy and ensure that every patient has an equal opportunity to receive the treatment that can save their lives, said Feinberg. Doing so requires innovation, passion and an entrepreneurial approach to the challenges at hand and we are excited to draw upon our 30 years of expertise as we embark on this next phase of our work.

About Gift of Life Marrow RegistryGift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life Marrow Registry, visitwww.giftoflife.org.

Read more from the original source:
gift of life marrow registry announces new center for cell and gene therapy - The Boca Raton Tribune

Recommendation and review posted by Bethany Smith